Development, Optimization, and Validation of a Multiplex Real-Time PCR Assay on the BD MAX Platform for Routine Diagnosis of Acanthamoeba Keratitis.
Acanthamoeba
/ genetics
Acanthamoeba Keratitis
/ diagnosis
Biopsy
Cornea
/ pathology
DNA, Protozoan
/ genetics
Diagnostic Tests, Routine
/ methods
Genotype
Humans
Molecular Diagnostic Techniques
/ methods
Multiplex Polymerase Chain Reaction
/ methods
Real-Time Polymerase Chain Reaction
/ methods
Reproducibility of Results
Sensitivity and Specificity
Journal
The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
10
02
2020
revised:
01
09
2020
accepted:
03
09
2020
pubmed:
26
9
2020
medline:
9
11
2021
entrez:
25
9
2020
Statut:
ppublish
Résumé
The reported number of cases of Acanthamoeba amebic keratitis (AK) is continually increasing. Molecular diagnosis has become the first choice of ophthalmologists for identifying and confirming this clinically problematic diagnosis. However, in-house molecular diagnostic procedures are time-consuming and may not be compatible with the urgency of the situation. In this study, a previous in-house AK-PCR technique was adapted for use on BD MAX (Becton Dickinson, Heidelberg, Germany), a fully integrated, automated platform for molecular biology, for the rapid routine diagnosis of AK. Different protocols were compared to optimize DNA extraction from Acanthamoeba cysts. The analytical parameters of the AK-BD MAX PCR were evaluated. Thirty-two samples were simultaneously tested with AK-BD MAX PCR and the original AK-PCR from which it was developed. A thermal-shock pretreatment protocol was validated. The analytical parameters obtained with BD MAX were similar to those obtained with the previous in-house AK-PCR method. The performance of AK-BD MAX PCR was then assessed for routine testing on 40 clinical samples, mostly corneal scrapings. Frozen, ready-to-use, in-house PCR premixes were stable over 8 months. Overall, 34 of the 40 clinical samples (85%) were considered to be true negatives; 4 (10%), probable AK; and 2 (5%), possible AK. This newly developed AK-BD MAX PCR is reliable, rapid, and efficient, and should facilitate Acanthamoeba keratitis diagnosis.
Identifiants
pubmed: 32976994
pii: S1525-1578(20)30459-1
doi: 10.1016/j.jmoldx.2020.09.001
pii:
doi:
Substances chimiques
DNA, Protozoan
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1400-1407Informations de copyright
Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.